The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Multicenter Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Abstract
Purpose: Bevacizumab improves survival in several solid tumor malignancies when combined with chemotherapy. We evaluated the efficacy and safety of the addition of bevacizumab to chemotherapy in the treatment of gastric and gastroesophageal junction (GEJ) adenocarcinoma. Patients and Methods: Forty-seven patients with metastatic or unresectable gastric/GEJ adenocarcinoma were treated with bevacizumab 15 mg/kg on day 1, irinotecan 65 mg/m 2, and cisplatin 30 mg/m 2 on days 1 and 8, every 21 days. The primary end point was to demonstrate a 50% improvement in time to progression over historical values. Secondary end points included safety, response, and survival. Results: Patient characteristics were as follows: median age 59 years (range, 25 to 75); Karnofsky performance status 90% (70% to 100%); male:female, 34:13; and gastric/GEJ, 24:23. With a median follow-up of 12.2 months, median time to progression was 8.3 months (95% CI, 5.5 to 9.9 months). In 34 patients with measurable disease, the overall response rate was 65% (95% CI, 46% to 80%). Median survival was 12.3 months (95% CI, 11.3 to 17.2 months). We observed no increase in chemotherapy related toxicity. Possible bevacizumab-related toxicity included a 28% incidence of grade 3 hypertension, two patients with a gastric perforation and one patient with a near perforation (6%), and one patient with a myocardial infarction (2%). Grade 3 to 4 thromboembolic events occurred in 25% of patients. Although the primary tumor was unresected in 40 patients, we observed only one patient with a significant upper gastrointestinal bleed. Conclusion: Bevacizumab can be safely given with chemotherapy even with primary gastric and GEJ tumors in place. The response rate, time to disease progression (TTP), and overall survival are encouraging, with TTP improved over historical controls by 75%. Further development of bevacizumab in gastric and GEJ cancers is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C., & Thun, M. J. (2006) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.56.2.106 · Cited by 5,314
Kamangar, F., Dores, G. M., & Anderson, W. F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.2308 · Cited by 3,434
Rising incidence of adenocarcinoma of the esophagus and gastric cardia
Blot, W. J. (1991) · JAMA · doi:10.1001/jama.265.10.1287 · Cited by 2,354
Kabbinavar, F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Lieberman, G., Griffing, S., & Bergsland, E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.066 · Cited by 1,716
Prognostic value of vascular endothelial growth factor expression in gastric carcinoma
Maeda, K., Chung, Y.-S., Ogawa, Y., Kang, S.-M., Ogawa, M., Sawada, T., & Sowa, M. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960301)77:5<858::aid-cncr8>3.0.co;2-a · Cited by 627
Ross, P., Nicolson, M., Cunningham, D., Valle, J., Seymour, M., Harper, P., Price, T., Anderson, H., Iveson, T., Hickish, T., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.105 · Cited by 475
Ohtsu, A., Shimada, Y., Shirao, K., Boku, N., Hyodo, I., Saito, H., Yamamichi, N., Miyata, Y., Ikeda, N., Yamamoto, S., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.130 · Cited by 427
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O’Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.2 · Cited by 344
Phase II Trial of Weekly Irinotecan Plus Cisplatin in Advanced Esophageal Cancer
Ilson, D. H., Saltz, L., Enzinger, P., Huang, Y., Kornblith, A., Gollub, M., O'Reilly, E., Schwartz, G., DeGroff, J., Gonzalez, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3270 · Cited by 268
Self-citationKarayiannakis, A. J., Syrigos, K. N., Polychronidis, A., Zbar, A., Kouraklis, G., Simopoulos, C., & Karatzas, G. (2002) · Annals of Surgery · doi:10.1097/00000658-200207000-00007 · Cited by 169
Ajani, J. A., Baker, J., Pisters, P. W. T., Ho, L., Mansfield, P. F., Feig, B. W., & Charnsangavej, C. (2002) · Cancer · doi:10.1002/cncr.10279 · Cited by 160
Pozzo, C., Barone, C., Szántó, J., Pádi, É., Peschel, C., Bükki, J., Горбунова, В. А., Valvere, V., Załuski, J., Biakhov, M. Y., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh473 · Cited by 158
Zon, R. T., Miller, K. D., Wang, M. J., Gralow, J. R., Dickler, M. N., Cobleigh, M., Perez, E. A., Shenkier, T., & Davidson, N. E. (2006) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(06)80030-3 · Cited by 134
Shah, M. A., Ilson, D. H., & Kelsen, D. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.81.908 · Cited by 119
Self-citationE2100: A Phase III Trial of Paclitaxel Versus Paclitaxel/Bevacizumab for Metastatic Breast Cancer
Miller, K. D. (2003) · Clinical Breast Cancer · doi:10.3816/cbc.2003.n.007 · Cited by 118
Kanai, T., Konno, H., Tanaka, T., Baba, M., Matsumoto, K., Nakamura, S., Yukita, A., Asano, M., Suzuki, H., & Baba, S. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980911)77:6<933::aid-ijc23>3.0.co;2-0 · Cited by 93
Dank, M., Załuski, J., Barone, C., Valvere, V., Peschel, C., Wenczl, M., Göker, E., Risse, M., Awad, L., & Bugat, R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.4003 · Cited by 87
Moiseyenko, V. M., Ajani, J. A., Tjulandin, S. A., Majlis, A., Constenla, M., Boni, C., Anelli, A., Yver, A., & Cutsem, E. V. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.4002 · Cited by 73
Parfitt, J. R., Miladinovic, Z., & Driman, D. K. (2006) · Canadian Journal of Gastroenterology · doi:10.1155/2006/175751 · Cited by 54
Cited by
Pennathur, A., Gibson, M. K., Jobe, B. A., & Luketich, J. D. (2013) · The Lancet · doi:10.1016/s0140-6736(12)60643-6 · Cited by 2,390
Ychou, M., Boige, V., Pignon, J.-P., Conroy, T., Bouché, O., Lebreton, G., Ducourtieux, M., Bedenne, L., Fabre, J.-M., Saint-Aubert, B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.0597 · Cited by 2,086
Ohtsu, A., Shah, M. A., Van Cutsem, E., Rha, S. Y., Sawaki, A., Park, S. R., Lim, H. Y., Yamada, Y., Wu, J., Langer, B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.2236 · Cited by 1,110
Self-citationProgress in the treatment of advanced gastric cancer
Song, Z., Wu, Y., Yang, J., Yang, D., & Fang, X. (2017) · Tumor Biology · doi:10.1177/1010428317714626 · Cited by 924
Lennerz, J. K., Kwak, E. L., Ackerman, A., Michael, M., Fox, S. B., Bergethon, K., Lauwers, G. Y., Christensen, J. G., Wilner, K. D., Haber, D. A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.4928 · Cited by 433
Metadata
- Authors
- Shah, M. A., Ramanathan, R. K., Ilson, D. H., Levnor, A., D'Adamo, D., O'Reilly, E., Tse, A., Trocola, R., Schwartz, L., Capanu, M., Schwartz, G. K., & Kelsen, D. P.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-11-20
- Volume
- 24
- Issue
- 33
- Pages
- 5201-5206
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2158118791
- Cited by
- 406
- References
- 21
- FWCI
- 34.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.